CGC-11047

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
CGC-11047
Accession Number
DB05722
Type
Small Molecule
Groups
Investigational
Description

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Synonyms
Not Available
External IDs
CGC 11047
Categories
UNII
HU43305R7O
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in lymphoma (unspecified), macular degeneration, prostate cancer, and solid tumors.

Pharmacodynamics

CGC-11047 is a polyamine analog with anti-proliferative properties. Polyamines are cell components considered essential for cell proliferation and differentiation. They are believed to work by displacing polyamines from their natural binding sites and preventing cell replication. CGC-11047 has been very well-tolerated in Phase I clinical trials and has demonstrated promising activity in patients with advanced disease.

Mechanism of action

The mechanism of action of CGC-11047 is unknown but it is believed to block the growth of cancer cells by blocking the production of new DNA in the cancer cells.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Mitchell JL, Thane TK, Sequeira JM, Marton LJ, Thokala R: Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids. 2007 Aug;33(2):291-7. Epub 2007 Apr 6. [PubMed:17410332]
  2. Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, Campochiaro PA: Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res. 2006 Nov;83(5):1260-7. Epub 2006 Sep 6. [PubMed:16950258]
  3. Loussouarn G, Marton LJ, Nichols CG: Molecular basis of inward rectification: structural features of the blocker defined by extended polyamine analogs. Mol Pharmacol. 2005 Aug;68(2):298-304. Epub 2005 May 4. [PubMed:15872118]
External Links
PubChem Substance
347910197

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAge Related Macular Degeneration (ARMD)1
1CompletedTreatmentMalignancies1
2TerminatedTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:27 / Updated on June 04, 2019 06:19